About Alveron Pharma
Alveron Pharma is a Healthcare company based in Nijmegen (Netherlands) founded in 2019. Drugs for haemorrhagic stroke and intracranial haemorrhage are developed. Alveron Pharma has raised $11.79 million across 3 funding rounds from investors including Rijksdienst voor Ondernemend Nederland, Oost NL and Thuja Capital. Alveron Pharma offers products and services including OKL-1111. Its focus areas include Life Sciences, Hematology, Drugs and Thromboembolic Disorders.
Company details
Alveron Pharma was founded in 2019 and is based in Nijmegen, Netherlands. Operations are centered in the pharmaceutical sector, where treatments for haemorrhagic stroke and intracranial haemorrhage are developed. Emphasis is placed on OKL-1111, a drug advanced as a rapid first-line therapy for intracranial hemorrhage. Research and development efforts are conducted to address these neurological conditions.
- Headquarters Nijmegen, Netherlands
- SectorsHealthcare
- Email••••••••
- Website alveron.com
- Total Equity Funding$11.79M (USD)
in 3 rounds
- Latest Funding Round$4.51M (USD), Series A
Oct 2021
- Investors
Products & Services of Alveron Pharma
Alveron Pharma offers a comprehensive portfolio of products and services, including OKL-1111.
Rapid treatment for haemorrhagic stroke to improve outcomes.
Funding Insights of Alveron Pharma
Alveron Pharma has successfully raised a total of $11.79M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.51 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.79M
- Total Rounds 3
- Last Round Series A — $4.51M
- First Round $7.28M
(May 2019)
- Investors Count 4
All 3 funding rounds of Alveron Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | Debt – Conventional | – | – | ||
| Oct 2021 | $4.51M | Series A | – | Thuja Capital, Waterman Ventures | – |
| May 2019 | $7.28M | Series A | – | Thuja Capital, Oost NL | – |
4 investors in total: 4 institutional.
Investors in Alveron Pharma
Alveron Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Rijksdienst voor Ondernemend Nederland, Oost NL and Thuja Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US | thujacapital.com | Utrecht, Netherlands | ||
Waterman Ventures is focused on supporting innovative growing businesses. | watermanventures.nl | Utrecht, Netherlands | ||
Sector-agnostic VC firm investing in geographies such as the Netherlands | 2003 | oostnl.nl | Apeldoorn, Netherlands | |
Provider of subsidies and financial support for businesses | 2014 | rvo.nl | Haag, Germany |
Investor details for Alveron Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alveron Pharma
16 people are tracked at Alveron Pharma (6 in leadership, 9 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Hash Patel | Chief Technical Officer | Leadership |
Edwin Spaans | Clinical Director | Leadership |
Stephan Peters | Founder & Chief Scientific Officer | Leadership |
Alex Zwiers | Chief Operating Officer | Leadership |
Ben Nichols | CEO | Leadership |
Harshad Patel | Chief Operating Officer | Leadership |
Michel Briejer | Board Member | Board & advisors |
Samuel Gerssen | Board Member | Board & advisors |
Pieter De Geus | Board Member | Board & advisors |
Joost Meijers | Advisor | Board & advisors |
Hugo ten Cate | Advisor | Board & advisors |
Nicola Mutch | Advisor | Board & advisors |
Jeff Weitz | Advisor | Board & advisors |
Adrian Parry-Jones | Advisor | Board & advisors |
Saskia Middeldorp | Advisor | Board & advisors |
Maxime Schreurs | Program Manager | Team |
Complete people profiles for Alveron Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alveron Pharma
3 dated milestones of Alveron Pharma across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Alveron Pharma is founded.
- Funding First funding round of $7.3M.
- Funding Latest funding round, Series A, of $4.5M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alveron Pharma
Complete news archive for Alveron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alveron Pharma
Alveron Pharma was founded in 2019.
Alveron Pharma is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Alveron Pharma is a funded company, having raised a total of $11.79M across 3 funding rounds to date. The company's 1st funding round was a Series A of $7.28M, raised on May 2019.
Alveron Pharma was founded in 2019 and is based in Nijmegen, Netherlands. Operations are centered in the pharmaceutical sector, where treatments for haemorrhagic stroke and intracranial haemorrhage are developed. Emphasis is placed on OKL-1111, a drug advanced as a rapid first-line therapy for intracranial hemorrhage. Research and development efforts are conducted to address these neurological conditions.
Alveron Pharma offers OKL-1111.
Alveron Pharma has 4 investors. Key investors include Rijksdienst voor Ondernemend Nederland, Oost NL, Thuja Capital, and Waterman Ventures.